Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | SCN4A | P35499 | 1/20 | 0.35 |
| ▸ | MC3R | P41968 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15813327 | 0.97 | TDP1 (0.47) | TDP1ALDH1A1MAPTKDM4EAGTR1 | |
| SCHEMBL13755285 | 0.94 | TDP1 (0.50) | TDP1ALDH1A1MAPTKDM4EAGTR1 | |
| SCHEMBL31602039 | 0.88 | TDP1 (0.39) | TDP1ALDH1A1MAPTKDM4EAGTR1 | |
| SCHEMBL13025468 | 0.85 | TDP1 (0.46) | TDP1ALDH1A1MAPTKDM4EAGTR1 | |
| SCHEMBL8391012 | 0.81 | TDP1 (0.67) | TDP1ALDH1A1MAPTKDM4EAGTR1 | |
| SCHEMBL14228148 | 0.81 | TDP1 (0.38) | TDP1 | |
| SCHEMBL1427782 | 0.78 | GABRR1 (0.35) | TDP1ALDH1A1MAPTKDM4EAGTR1 | |
| SCHEMBL11554828 | 0.78 | CES2 (0.41) | ALDH1A1MAPTKDM4EAGTR1LMNA | |
| SCHEMBL14331808 | 0.76 | LDHA (0.38) | TDP1ALDH1A1MAPTKDM4EAGTR1 | |
| SCHEMBL12301958 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1006140-B1 | Process for the preparation of siloxane-oxyalkylene copolymers | GEN ELECTRIC (US) | 2004-07-14 | — | — | EP | claimed |
| US-6372874-B1 | SOLVENT-FREE HYDROSILATION OF UNSATURATED POLYETHERS WITH ORGANOHYDROGENSILOXANES IN THE PRESENCE OF HYDROXYL, CARBONYL, OR ETHER-FUNCTIONAL AMINES AS BUFFERS FOR THE METAL HYDROSILATION CATALYSTS; BY-PRODUCT INHIBITION; KINETICS | CROMPTON CORPORATION | 2002-04-16 | — | — | US | claimed |
| EP-1006140-A2 | Process for the preparation of siloxane-oxyalkylene copolymers | CK WITCO CORPORATION (US) | 2000-06-07 | — | — | EP | claimed |
| CN-117899939-A | Preparation method of titanium catalyst and application of titanium catalyst in organic silicon sealant | 浙江中天东方氟硅材料股份有限公司 | 2024-04-19 | — | — | CN | disclosed |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210078983-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Cellix Bio Provate Limited (IN) | 2021-03-18 | — | — | US | disclosed |
| US-10858349-B2 | Compositions and methods for the treatment of cancer | CELLIX BIO PRIVATE LIMITED (IN) | 2020-12-08 | — | — | US | disclosed |
| US-20190292171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | CELLIX BIO PRIVATE LIMITED (IN) | 2019-09-26 | — | — | US | disclosed |
| US-9669015-B2 | Piperidine-2, 6-dione derivatives and their use as tumor necrosis factor inhibitors | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2017-06-06 | — | — | US | disclosed |
| US-8367691-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-08 | — | — | US | disclosed |
| US-20100311746-A1 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-09 | — | — | US | disclosed |
| EP-1006140-B1 | Process for the preparation of siloxane-oxyalkylene copolymers | GEN ELECTRIC (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1263756-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | Bristol-Myers Squibb Pharma Company (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6372874-B1 | SOLVENT-FREE HYDROSILATION OF UNSATURATED POLYETHERS WITH ORGANOHYDROGENSILOXANES IN THE PRESENCE OF HYDROXYL, CARBONYL, OR ETHER-FUNCTIONAL AMINES AS BUFFERS FOR THE METAL HYDROSILATION CATALYSTS; BY-PRODUCT INHIBITION; KINETICS | CROMPTON CORPORATION | 2002-04-16 | — | — | US | disclosed |
| WO-2001070734-A2 | BETA-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-ALPHA | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-1006140-A2 | Process for the preparation of siloxane-oxyalkylene copolymers | CK WITCO CORPORATION (US) | 2000-06-07 | — | — | EP | disclosed |
| EP-0329268-A2 | Glass ionomer dental cement curable in two stages | Kerr Manufacturing Company (a Delaware corporation) (US) | 1989-08-23 | — | — | EP | disclosed |
| US-3956316-A | PROGESTATIONAL AND SALT-RETAINING AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078983-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | SI, HBG2, HBG1 | TDP1 4206/4885ALDH1A1 2768/4885MAPT 2211/4885 |
| US-20100311746-A1 | MODULATORS OF MUSCARINIC RECEPTORS | CHRM3, CHRM5, CHRM2 | TDP1 4014/4885ALDH1A1 2356/4885MAPT 2337/4885 |
| US-20190292171-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | SI, HBG2, HBG1 | TDP1 4206/4885ALDH1A1 2768/4885MAPT 2211/4885 |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | TDP1 2577/4885ALDH1A1 2100/4885MAPT 4850/4885 |
| US-10858349-B2 | Compositions and methods for the treatment of cancer | SI, HBG2, HBG1 | TDP1 4206/4885ALDH1A1 2768/4885MAPT 2211/4885 |
| US-20120283243-A1 | Spiroindoline Modulators of Muscarinic Receptors | CHRM3, CHRM2, CHRM5 | TDP1 4213/4885ALDH1A1 1353/4885MAPT 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.